Sermorelin and Ipamorelin are two distinct synthetic peptides classified as a Growth Hormone Releasing Hormone (GHRH) analog and a Growth Hormone Releasing Peptide (GHRP) respectively, often utilized in combination to stimulate the pituitary gland. Their combined use aims to restore a more youthful, pulsatile pattern of endogenous growth hormone (GH) secretion. This synergistic approach supports anti-aging objectives, including improved body composition and tissue repair.
Origin
Sermorelin, a GHRH analog, was developed in the 1980s as a truncated version of the naturally occurring GHRH. Ipamorelin, a selective GHRP, emerged later, designed to mimic ghrelin’s action without significantly affecting cortisol or prolactin release. Their combined use in clinical practice is a strategy to maximize the physiological GH pulse amplitude and frequency.
Mechanism
Sermorelin binds to GHRH receptors on the somatotrophs, directly stimulating GH synthesis and release. Ipamorelin acts on the ghrelin receptor (GHSR-1a), further amplifying the GH pulse by inhibiting somatostatin and promoting a more robust release. The simultaneous activation of both pathways creates a powerful, yet physiological, release of GH, which then drives the production of IGF-1 from the liver.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.